A new publication from our group

We are happy to share our new publication about a modified version of PD-1 receptor, or how to turn something negative to an enhancing molecule. There have been a few reports this year showing technologies similar to ours, suggesting that interest for associated molecules to increase the binding might represent a solution to improve cell -based therapy. We thank all co-authors and of course our support: Helse Sør Øst, The Research Council of Norway and The Norwegian Cancer Society

“Built-in” PD-1 blocker to rescue NK-92 activity from PD-L1–mediated tumor escape mechanisms

Page visits: 35